Trials
29 active
52 in total · 34 in the EU
Targets
—
None known yet
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- How it’s given
- “Participants continue ribociclib in combination with goserelin as was administered in their parent study”In the company’s words, NCT05161195 on ClinicalTrials.gov
- Tested for
- Early Breast Cancer (2 trials), Breast Cancer (2 trials), Metastatic Breast Cancer, Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies, Melanoma, Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer and 1 more
- Main trialPhase 4
- “The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a Novartis-sponsored global study that has reached its primary objective(s).”In the company’s words, NCT05161195 on ClinicalTrials.gov
- Other names
- LEE011 · Kisqali
Other drugs for Early Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up9
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
- 1 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 2 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 12 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
- 25 Sep 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 7 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
- 29 May 2030Phase 3 trial completes · ClinicalTrials.gov
- 28 Jun 2030Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials52
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 28 Jun 2030 | Roll-over Study to Allow Continued Access to Ribociclib | |
| Phase 3Active, not recruiting | 7 Sep 2029 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | |
| Phase 3Active, not recruiting | 29 May 2030 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer | |
| Phase 2Active, not recruiting | 1 Feb 2027 | Ribociclib (LEE011) Rollover Study for Continued Access | |
| Phase 2Active, not recruiting | 2 Feb 2027 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | |
| Phase 1/2Active, not recruiting | 26 Feb 2027 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | |
| Phase 1/2Recruiting | 25 Sep 2028 | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors | |
| Phase 1Active, not recruiting | 30 Dec 2026 | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | |
| Phase 1Active, not recruiting | 12 Jul 2027 | Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | |
| Phase 3Completed | 29 Jan 2016 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer | |
| Phase 3Completed | 21 Aug 2017 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | |
| Phase 3Completed | 3 Nov 2017 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. | |
| Phase 3Completed | 11 Dec 2018 | Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer | |
| Phase 3Completed | 8 Nov 2019 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC | |
| Phase 3Terminated | 11 Dec 2023 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant | |
| Phase 2Completed | 9 Mar 2020 | Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer | |
| Phase 2Completed | 11 Jun 2021 | Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer | |
| Phase 2Completed | 12 Apr 2022 | Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer | |
| Phase 2Completed | 25 Apr 2022 | Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | |
| Phase 2Completed | 30 Dec 2022 | Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | |
| Phase 1/2Completed | 25 Feb 2020 | Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. | |
| Phase 1/2Terminated | 28 Sep 2026 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | |
| Phase 1Completed | 14 Mar 2018 | Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | |
| Phase 1Completed | 9 Nov 2020 | Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis | |
| Phase 1Terminated | 13 Sep 2021 | Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | |
| Phase 1Completed | 29 Sep 2022 | A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | |
| Phase 1Terminated | 15 Jan 2024 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | |
| Phase 1Terminated | 24 Apr 2024 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | |
| Phase 1Terminated | 26 Feb 2025 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | |
| Phase 4Authorised | not given | CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS | |
| Phase 2Authorised | not given | A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE | |
| Phase 1/2Ended | not given | Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in breast cancer, with positive hormone receptors and negative HER2 status, in newly diagnosed, not immediately operable (or wishing to avoid surgery), elderly patient | |
| Phase 2Ended | not given | SAFIR 03_A ctDNA screening program in patients with HR+, HER2- metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations. | |
| Phase 2Authorised | not given | Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized low-intervention phase II trial of the AIO working groups breast cancer and quality of life | |
| Phase 2Authorised | not given | ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer | |
| Phase 3/4Authorised | not given | IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-controlled trial (IMPORTANT trial) | |
| Phase 2Authorised | not given | Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer (RIBOLARIS) | |
| Phase 3Ended | not given | A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA | |
| Phase 4Authorised | not given | zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention | |
| Phase 2Authorised | not given | MegaMOST - A multicenter, open-label, biology driven, Phase II study evaluating the activity of anti-cancer treatments targeting tumor molecular alterations/characteristics in advanced / metastatic tumors | |
| Phase 3Authorised | not given | Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk, HR+/HER2- early breast cancer (ADAPTcycle) | |
| Phase 3Authorised | not given | Selecting the optimal position of CDK4/6 inhibitors in HR+ advanced breast cancer: the SONIA trial | |
| Phase 2Authorised | not given | PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER (THE CADILLAC STUDY) | |
| Phase 4Authorised | not given | TYPER– A Randomized Controlled Study Evaluating the Effectiveness of Typology-based Coaching on Therapy Management for Patients with HR+ HER2- Early Breast Cancer Under Adjuvant Treatment with Ribociclib | |
| Phase 4Authorised | not given | SPatial Heterogeneity of INtratumoral drug distribution | |
| Phase 3Authorised | not given | NoLEEta - No chemotherapy in intermediate-risk HR+ HER2- early breast cancer treated with Ribociclib (LEE-011) in the adjuvant setting, a noninferiority Phase III trial | |
| Phase 3Authorised | not given | Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela) | |
| Phase 4Authorised | not given | Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study" | |
| Phase 4Authorised | not given | Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG | |
| Phase 3Authorised | not given | DECEMBER: De Escalation of CDK4/6 inhibitors for ER+ HER2- Metastatic BrEast Cancer in complete Response | |
| Phase 1/2Authorised | not given | A phase Ib/II of chemotherapy-free trial evaluating Zongertinib in combination with Ribociclib, Endocrine Therapy and Trastuzumab in patients with ER-positive/HER2-positive metastatic breast cancer - PATRICIA-3 - | |
| Phase 2Authorised | not given | Optimization of De-EscalatiON strategies in early breast cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026